Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Rai on Novel Approaches in CLL

February 28th 2017

Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses some novel approaches being used in the field of chronic lymphocytic leukemia.

Dr. Brown Discusses Acalabrutinib in CLL

February 28th 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).

Researchers Examine Acquired Mutations Linked to Ibrutinib Resistance in CLL

February 25th 2017

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

Dr. Jain on PD-1 Expression in Nivolumab/Ibrutinib Combination in CLL

February 24th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).

Dr. Jones on Studying Venetoclax in R/R CLL

February 24th 2017

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

Dr. Jones on the Safety of Venetoclax in CLL

February 23rd 2017

Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Wierda on Ibrutinib Plus Venetoclax in CLL

February 22nd 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

Dr. Woyach on Phase II Trial of MOR208 Trial in CLL

February 18th 2017

Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.

Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

February 10th 2017

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Study Identifies Potential Biomarkers for CAR T-Cell Therapy Response in CLL

February 10th 2017

A study presented at the 2016 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.

Dr. Woyach on Preliminary Efficacy Results of MOR208 Trial in CLL

February 7th 2017

Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the preliminary efficacy results of the MOR208 trial in chronic lymphocytic leukemia (CLL).

Upfront Ibrutinib Continues to Impress in CLL

February 3rd 2017

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Expert Discusses Value of Venetoclax After BCR Inhibition in CLL

February 3rd 2017

Jeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.

Dr. Tam Discusses BTK Inhibition in CLL

February 3rd 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BTK inhibition in chronic lymphocytic leukemia (CLL).

MOR208 Combo Regimens Show Early Promise in CLL

January 27th 2017

Jennifer A. Woyach, MD, discusses the preliminary results of an ongoing phase II trial of MOR208 combination regimens in chronic lymphocytic leukemia.

Dr. Leis on Promising Combo Regimens Being Explored in CLL

January 24th 2017

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses combination regimens that seem promising and are under investigation in the treatment landscape of chronic lymphocytic leukemia.

Dr. Tam on BTK Inhibitor BGB-3111 in CLL

January 21st 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses BGB-3111, a new BTK inhibitor being used in the treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Woyach on Ibrutinib Resistance in CLL

January 21st 2017

Jennifer Woyach, MD, associate professor, The Ohio State University, discusses ibrutinib resistance in patients with chronic lymphocytic leukemia.

Dr. Leblond on Treatment Landscape of CLL

January 20th 2017

Veronique Leblond, MD, of Pietra - Hospital, Paris, France, discusses the current treatment landscape of chronic lymphocytic leukemia (CLL).

BTK Inhibitors Mushroom in Blood Cancer Field

January 20th 2017

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.